Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi BOJO
I'm no expert on how BioTech's interact at the enquiry level but we do know that NDA's form a basis for opening discussions. I see no reason why an NDA could not extend to proving the capability of increasing the Avidity of an existing Mab product.
Maybe we are already doing that in-house as part of our sales and marketing budget.
Chester.
Hi VanVan
I've been out all day so only just had chance to respond. I think miavoce's reply is a good part of where we are on the deals front.
My honest take on AvidiMab is that it has the potential to be taken up by dozens of Mab related Biotech and Pharma Companies but it will take time to convince them and then lab test each new product. When the first deal is signed it will give confidence to other Co's to test AvidMab on their products. This process could take another year at least. When AvidiMab has been proven to improve the Avidity of a third party Mab and that translates to better clinical outcomes in an already licensed product, it will lead to even more deals.
The GlyMab situation is different because GenMab have already given the first green light and stumped up £5M to tie up an exclusive deal for a Target ( Oct 22 ). It was way easier to sell that to GenMab because they have known and worked with Scancell for many years. We still need to hear that GenMab are going to enter a Ph1 Trial using our GlyMab Target.
Selling other GlyMabs or 'Target of a GlyMab' will take a lot of time but getting another deal over the line will make the next deal easier and so on.
I'm not convinced we will see much in the way of new deals in 2024 but its pretty obvious that Scancell are already having multiple discussions on both AvidiMab and the GlyMabs, hopefully any potential buyers will be in a rush to get a deal done.
So much can happen this year and let's hope it's at least a continuation of strong and positive results across all cohorts of both trials.
Chester.
Hi VanVan
I agree with you that Scancell has had to react as the science / investment picture changed. Their was a fantastic article linked on here in the last few weeks that talked about the strategy being employed by many BioTechs.
Under the guidance of our new ( 12 months + ) Chairman we have ensured that cash is in place to allow some freedom of choice over the next year and a half.
Our CEO has said a few times that as the trials progress and the data becomes more compelling the deeper any suitor will have to go into their pockets.
It does seem that the SCOPE Trial is on track to produce results that the owner of the Checkpoint Inhibitors will find it almost impossible to resist. If SCIB1 and then iSCIB+ pan out as hoped for in the recent RNS, Bristol Myers Squibb could see an opportunity to be dominant in that market. The addition of AvidiMab would give an extended patent life of 15 years.
If the ModiFY Trial shows similar results in the Checkpoint Inhibitor cohorts both of our platforms will become very coveted by many Large Pharma Cos, as many of them need to build their future pipelines with cutting edge treatments.
As has been the mantra here for many years, what creates the value is 'data data data' and 2024 should see enough clinical results to finally get the share price on its way beyond 30p. Add to that the values of any deals done for either GlyMabs or AvidiMab.
Could be a fantastic year for you if Scancell take off and Greatland Gold start bringing Havieron to life.
Chester.
Great summation to my Question, thanks Ray,
It will be a glorious day when the long dreamed of potential actually translates into to patients being given their lives back. It is one thing to be an investor in Scancells endeavours and not knowing if that day will actually come about.
To be someone told that there is nothing further that can be done in their struggle against their illness and then in the 'last chance saloon' Immunobody gives them back years of life to enjoy with loved ones ....... that is amazing. Where we could be in 5 years time probably looks like science fiction in 2024.
Fingers crossed it comes about and progresses as you have outlined.
Chester.
After re-reading the SCOPE Trial update dated 27th November 23, I have a question ?
Taken from that RNS :
"The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs. Recruitment is on track with data available in H1 2024. Based upon the first 13 patients there is a greater than 90% probability that the second phase will also be successful.
If validated in the second stage of the SCOPE trial this will provide confidence to initiate a randomised phase 2/3 adapted registration programme in patients with unresectable melanoma which represents a potential $1.5 billion per annum market. The Phase 2 part of the adapted trial should take 18 months and will likely generate significant partner interest".
So if the success of SCIB1 Monotherapy can open up a $1.5B yearly market, does that mean that if iSCIB+ is just as successful that the yearly market size becomes somewhere around $3.75B ?
Chester.
Hi Defender90
The market simply wants to see value.
A milestone payment from GenMab or another Deal with GenMab, with an another upfront payment.
A new Pharma co or two doing deals for one or more of our GlyMabs or an AvidiMab deal.
Trial Wise :
The number of positive responses on the Scope Trial going past 30 patients and reaching 90% ORR.
Outstanding results from the early patients on Modi1 + Checkpoints, showing tumour reduction.
All of the above would not only raise the SP but start to persuade Institutional Investors to take longterm position.
I think a tipping point could be created by a combination of 'Positive Trial Data' and 'Deals' involving cash that will start the journey towards Violindog's 50p target.
Chester.
I agree C11
'Those that follow the science' is probably a better way of putting it.
I really do hope we see some data for the first few patients on Modi1 + Checkpoints. It is a piece of the puzzle I'm waiting for with the hope it's on par with the Scope achievements.
Chester.
The important issue is that the current SP is stuck very close to the fund raise. This can only break upwards on positive news. Either trial related or deals.
The worth of the SCOPE, iSCIB+ approval is yet to be seen but as LTH's we can see how it could impact on the future value of the company.
In the next week or so, we could have new information on both Trials as some patients will have reached and passed their 1st Scans for SCIB1+ CPI and MODI1 + CPI since the last updates.
The 6 month assessment by a 'Large Pharma Co' on our GlyMabs should be complete and a decision or discussions being held.
A remote possibility that GenMab have decided to register for a Phase1 trial, triggering a small Milestone. They were even interested in another target / Mab, so news on that could be imminent.
All of the above are the kind of positive announcements that will get the SP moving back towards 20p. Which I feel we should already be at.
Chester.
Scancell's share price is currently floating around 11p even though we have two incredible trials running, 61 highly capable staff and roughly £15m in cash.
Back when we had 230m shares in issue and only the promise of what Immunobody or Moditope could achieve the share price was circa 5p.
I remember thinking what a steal 5p was set against the potential waiting to be unlocked.
I'm back to thinking the same now about 11p.
Based only on the data released so far from the SCOPE trial and the confidence shown by LD in the potential of iSCIB+. Added to that, If Modi1 + CPI'S has anything like the same impact on positive treatment outcomes 11p becomes a serious joke.
When we reach the end of this year I honestly think we will look back at this current 11p as a gift for those that took advantage.
To all Scancell shareholders I say, 'stay patience and keep the faith' 2024 is already loaded up with the potential of many inflection points.
Chester.
Hi C7
Great to hear from you.
This excellent and timely RNS does set up the Iterim Report very nicely.
I'm not interested in how the market reacts at this time as the importance of each of these excellent pieces of news is that they continue to add value going forward.
Chester.
Hi TF
The fact is that three new investors have taken a position in the last cash raise. We can only presume that they did some Due Diligence and they were not just having a punt.
We have been told that Large Pharma wants to see solid data, the kind that reduces the risk of a bad investment.
Our new found investors will have the appetite for a little more risk / reward. So I'm delighted to see them on board.
The next set of 'Positive' data results will see Scancell taken very seriously.
Chester.
Hi Violindog
I think that the fact that three new industry investors have just climbed aboard tells us that Scancell are becoming a prime target.
The next set of results will place Immunobody and Moditope at the top of many Large Pharma lists of possible acquisitions.
Chester.
There is a good probability that we will hear how the trial for Modi1 + CPi ( Anti PD1 only ) in Renal & Head and Neck cancers is proceeding.
31st July that Cohort was approved and the aim was to enrol 21 patients in each setting.
By the Interim Report there will have been a time period of some 25 weeks to Enrol, have 1st dose and reach 1st scan for a number of patients. Based on previous updates we should be given an overview for part of those cohorts.
In the Neoadjuvant Cohort the 1st patient was not dosed until 30th November ( confirmed at the AGM ).
The procedure was to take a biopsy then 2 x doses of Modi1 3 weeks apart and then resection of the tumour 6 weeks later. The very 1st patient will not reach the resection stage until the end of this month at the earliest.
So on Modi1 + CPI, I would expect details on the numbers of enrolled patients and some information about the resulting 1st scans of those reaching that point. Similar to last years update RNS.
Chester.
Having been invested in Scancell for a decade, I am also frustrated by the current shareprice as it feels like it should be much higher. Part of that is solely due to the fact that we have been above 20p several times and seemed to be one piece of good news from heading higher. I don't think being on the AIM market helps either.
What we do know is that Scancell's platforms have the potential to be worth many multiples of 11p.
Chester.
What can we expect from the Half Yearly Update, due at the end of this month ?
Last year we were told how the trials were progressing and the numbers of enrolled patients. Should we expect a detailed update on both SCOPE and ModiFY ?
Chester.
Scancell's share price is currently floating around 11p even though we have two incredible trials running, 61 highly capable staff and roughly £15m in cash.
Back when we had 230m shares in issue and only the promise of what Immunobody or Moditope could achieve the share price was circa 5p.
I remember thinking what a steal 5p was set against the potential waiting to be unlocked.
I'm back to thinking the same now about 11p.
Based only on the data released so far from the SCOPE trial and the confidence shown by LD in the potential of iSCIB+. Added to that, If Modi1 + CPI'S has anything like the same impact on positive treatment outcomes 11p becomes a serious joke.
When we reach the end of this year I honestly think we will look back at this current 11p as a gift for those that took advantage.
To all Scancell shareholders I say, 'stay patience and keep the faith' 2024 is already loaded up with the potential of many inflection points.
Chester.
Happy New Year All.
Did someone recently post that the JP Mogan event is by invitation only ?
If that's the case, Sath going is really good news for Scancell. Shows there is real interest in the clinical trial results so far.
Chester.
The Circular is on Scancells website.
Under INVESTOR, find 2023 Capital Raise.
Click on 'I am located elsewhere'. Find and Click on 'Agree' which is at the bottom of the page.
Now choose, Scancell Circular November 2023.
That is the whole document which you will need to sift through. The important note is that the offer must be applied for by tomorrow 5th December.
Hope that helps.
Chester.